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surveillance purposes. However, be-
cause of the small number of inﬂ  uenza 
virus (H5N1) case-patients, our study 
was too underpowered to draw any 
ﬁ   rm conclusions; results should be 
interpreted cautiously. In a study of   
cases in Vietnam, 5 case-patients did 
not have any identiﬁ  ed exposure <7 
days of illness onset (10). In China, 
the exposure period for surveillance 
of suspected cases now includes ex-
posure to a wet poultry market <14 
days before illness onset. Although 
data on person-to-person virus trans-
mission are limited, close contacts 
of patients infected with inﬂ  uenza 
virus (H5N1) in China are monitored 
daily for 10 days after the last known 
exposure. Further studies are needed to 
quantify the incubation period after ex-
posure to sick or dead infected poultry, 
a wet poultry market, or to an inﬂ  uenza 
A virus (H5N1) case-patient and to in-
vestigate the basis for any differences. 
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Mycobacterium 
haemophilum 
Infection after 
Alemtuzumab 
Treatment
To the Editor: The immuno-
suppressive agent alemtuzumab is a 
DNA-derived, humanized monoclonal 
antibody directed against the panlym-
phocyte, cell-surface antigen CD52 (1). 
The drug is approved for the treatment 
of refractory B-cell chronic lympho-
cytic leukemia (2) and also has been 
used after stem cell (3) and organ trans-
plantations (4). Alemtuzumab causes 
profound and prolonged lymphocyte 
depletion, which results in a variety of 
complications involving infections (5). 
However, mycobacteria have rarely 
been reported to cause infection after 
alemtuzumab treatment. We describe 
infections with Mycobacterium hae-
mophilum, a fastidious nontuberculous 
mycobacterium, in 2 patients who ex-
perienced cutaneous lesions while they 
received alemtuzumab.
Patient 1
A 65-year-old man with refrac-
tory chronic lymphocytic leukemia 
had been receiving treatment with 
alemtuzumab for 3 months. During 
a 5-week period beginning 15 weeks 
after the alemtuzumab therapy started, 
20–30 tender nodular-ulcerative le-
sions developed on the patient’s ex-
tremities. Most of the lesions were 
distributed along a saphenous vein site 
(Figure). Immediately before receiv-
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ing alemtuzumab, he had been given 
rituximab for 3 months. A punch bi-
opsy of the cutaneous lesion showed 
lymphogranulomatous inﬂ  ammation 
in the dermis. Acid-fast stains of the 
skin punch biopsy specimen, as well 
as aspirated material from the le-
sions, demonstrated acid-fast bacilli. 
Cultures on Middlebrook 7H11 agar 
(Becton Dickinson and Company, 
Sparks, MD, USA) containing X-fac-
tor strips incubated at 30°C showed 
growth of the acid-fast bacilli after 13 
days. The isolate was subsequently 
identiﬁ  ed as M. haemophilum by us-
ing conventional biochemical proﬁ  les 
and assessment of morphologic fea-
tures, including an optimal growth 
temperature of 30°C and a hemin re-
quirement. The patient was treated 
with 4 drugs (rifampin, doxycycline, 
clarithromycin, ciproﬂ  oxacin),  and 
he rapidly improved. Susceptibility 
testing, using broth MIC determina-
tions described in Clinical and Labo-
ratory Standards Institute publication 
M-24A (www.clsi.org/source/orders/
free/m24-aa.pdf), indicated that the 
isolate was sensitive to clarithromy-
cin, ciproﬂ   oxacin, clofazimine, and 
linezolid; intermediately sensitive to 
rifampin; but resistant to rifabutin, 
doxycycline, ethambutol, streptomy-
cin, and amikacin. The antimicrobial 
drugs the patient was receiving were 
changed to only rifampin, clarithro-
mycin, and ciproﬂ   oxacin. He com-
pleted a 6-month course of treatment 
without recurrence of the lesions.
Patient 2
A 17-year-old woman with severe 
systemic lupus erythematosus and 
secondary myelodysplastic syndrome 
received an unrelated T-cell depleted 
bone marrow transplant. Her condi-
tioning regimen included melphalan, 
thiotepa, ﬂ  udarabine, and 2 doses of 
alemtuzumab. She initially did well 
posttransplant and was discharged 
from the hospital Approximately 3 
months later, 40–50 tender erythema-
tous papular lesions developed on her 
extremities. A skin biopsy specimen 
showed mycobacterial panniculitis. 
Cultures from skin, blood, and bone 
marrow grew M. haemophilum af-
ter 18–19 days’ incubation. She was 
successfully treated with rifampin, 
clarithromycin, and gatiﬂ  oxacin; how-
ever, she died several months later 
from unrelated complications.
M. haemophilum was ﬁ  rst  de-
scribed in 1978 when it was isolated 
from cutaneous lesions of a woman 
from Israel with Hodgkin disease (6). 
M. haemophilum most often causes 
joint, cutaneous, and pulmonary in-
fections in immunocompromised 
patients (7) and lymphadenitis in im-
munocompetent children (8). M. hae-
mophilum is a fastidious organism 
that requires media supplemented 
with ferric ions in the form of hemin, 
hemoglobin, or ferric ammonium 
citrate, and incubation at 30°C–32-
°C for several weeks. On the basis of 
our experience at Memorial Sloan-
Kettering Cancer Center (23 cases of 
M. haemophilum infection observed 
from 1990 through 2000) (9), the fol-
lowing specimens are routinely set 
up for culture: blood smear speci-
mens that are positive for acid-fast 
bacilli, synovial or joint ﬂ  uids, skin 
biopsy specimens, cutaneous lesions, 
ulcers, abscesses, lymph nodes, and 
lung biopsy specimens. Culture me-
dia include Middlebrook 7H11 agar 
plates with a hemin-containing paper 
strip (X-factor) placed on the agar 
surface that are then incubated at 
30°C for 6 weeks. Growth of the or-
ganism is usually detected within 2 to 
3 weeks, and the isolates are usually 
susceptible in vitro to the quinolones, 
macrolides, and rifamycins and resis-
tant to several drugs for tuberculosis, 
including ethambutol, isoniazid, and 
pyrazinamide (9).
Alemtuzumab has been associ-
ated with the development of infec-
tions caused by a variety of microor-
ganisms. However, mycobacteria have 
infrequently been the reported cause. 
In a review of 547 organ transplant 
recipients who received alemtuzumab 
treatment, miliary tuberculosis devel-
oped in 1 recipient of a kidney trans-
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Figure. Nodular-ulcerative skin lesions on the left thigh caused by Mycobacterium 
haemophilum infection in a patient with chronic lymphocytic leukemia (patient 1) whose 
condition had been treated with alemtuzumab. LETTERS
plant, and pulmonary infection with 
M. kansasii developed in 2 recipients 
of lung transplants (5). There is also 
a case report of systemic M. bovis in-
fection developing in a patient with 
relapsing B chronic lymphocytic leu-
kemia after administration of alemtu-
zumab (10).
Although we believe that alem-
tuzumab is responsible for the severe 
immunosuppression that predisposed 
these patients to M. haemophilum in-
fection, other explanations are plau-
sible. For example, patient 1 had re-
ceived rituximab and cyclophosamide 
for 6 months. These drugs, in addition 
to his underlying disease of chromic 
lymphocytic leukemia, may have pre-
disposed him to M. haemophilum in-
fection. However, his lesions did not 
appear until he received alemtuzumab. 
In patient 2, the immunosuppression 
associated with his transplant may 
have predisposed the patient to M. 
haemophilum infection.
This report identiﬁ  es M. haemo-
philum as an opportunistic pathogen 
in patients who have received alem-
tuzumab. We recommend that all 
patients who have received at least 1 
dose of alemtuzumab, and who have 
undiagnosed tender skin lesions lo-
cated over the extremities, be evalu-
ated by using appropriate techniques 
to isolate M. haemophilum. Commu-
nication with microbiology laborato-
ry staff concerning appropriate meth-
ods for detection of the organism is 
crucial.
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Prior Evidence of 
Putative Novel 
Rhinovirus Species, 
Australia
To the Editor: Briese et al. (1) are 
to be congratulated for their delineation 
of the global geographic presence of 
human rhinovirus (HRV) strains simi-
lar to those reported in 2006 from one 
third of cases of an otherwise patho-
gen-negative respiratory outbreak in 
New York. Of equal importance is the 
temporal occurrence of these strains. 
Although it is intriguing to suggest, 
on the basis of limited sequence data, 
that these strains were circulating at 
least 2 centuries earlier (1), Briese et 
al. neglect to acknowledge empirical 
evidence that what we now call HRV- 
C strains circulated before 2004–2005. 
Unculturable PCR-positive rhinovi-
ruses were reported in 1993; however, 
more compelling is the fact that sub-
genomic sequence and phylogenetic 
data were reported from Belgium (2), 
Australia (3), and then New York (4). 
The Belgium noncoding sequences 
were reported in 2006 but originated 
from specimens collected in 1998–
1999. Australian coding sequences 
from 2003 to 2004 were assigned, for 
the ﬁ  rst time, to a novel clade called 
HRV-A2, reﬂ  ecting both their phylo-
genetic isolation and branching from 
the known HRV-A strains (3). 
It can be deduced that NY-041 
and NY-060, strains from the 2004 
New York winter outbreak, are vari-
ants (>98% amino acid identity) of 
the ﬁ  rst characterized HRV-A2 strain, 
HRV-QPM (4,5). More recently, we 
proposed that the HRV-A2 strains di-
verged sufﬁ  ciently to meet several of 
the International Committee on Taxon-
omy of Viruses criteria for classifying 
a putative new species, HRV-C (6).
It is an exciting time for those in-
terested in rhinoviruses. With increased 
implementation of multiplexed screen-
ing approaches (such as the MassTag 
PCR), or by simply including a speciﬁ  c 
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